HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $21
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $24 to $21.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $24 to $21.